Humanin

What is humanin, and where did it come from?

Humanin was found in 2001 during a functional screen at Keio University in Tokyo. The researchers identified a gene that prevents nerve cell death caused by different gene mutations leading to familial Alzheimer’s disease and by the amyloid beta protein, and named it humanin. The gene transferred into cells was translated into a short polypeptide and secreted into the culture medium; the protective effect depended on the peptide’s amino acid sequence. In the same study, humanin did not prevent cell death caused by other causes (polyglutamine Q79 or SOD1 mutants). ^[1]

According to a 2023 systematic review, humanin is encoded in a short open reading frame within the 16S ribosomal RNA gene (MTRNR2) of mitochondrial DNA; depending on whether it is translated in the mitochondrion or in the cytoplasm, it can be 21 or 24 amino acids long, and it is the first member of a family called mitochondrial-derived peptides (MDPs). The review writes that humanin has been described as a peptide that helps preserve mitochondrial function and cell viability under stress and aging conditions, but that the mechanisms related to aging have not yet been fully clarified. ^[2] A peptide from the same family, encoded in another region of mitochondrial DNA, is covered in a separate guide: MOTS-c

Is natural humanin the same as the product sold?

In a significant portion of the animal studies, what was used was not natural humanin but an analog (humanin-S14G, HNG for short) with a change at the 14th amino acid, reported to be more potent. ^[4] Findings referred to as “humanin” therefore do not always belong to the natural peptide. Which form a product sold online as “for research purposes” is, and its purity and sterility, are not checked.

What do the cell and animal studies show?

These findings show that humanin is a biologically interesting molecule. However, every row of the table belongs either to cell culture or to rodents; whether the same effects occur in humans has never been tested.

The lifespan and aging claim

The source of the claim “humanin extends lifespan” is a 2020 study. In this study, excess humanin extended lifespan in worms (C. elegans). Middle-aged (18-month-old) female mice were given HNG at regular intervals for 14 months: body weight ran lower than in the control group, visceral fat decreased and lean mass increased in a measurement of 5 mice each at month 28, and IGF-1 fell; however, at the end of the 14-month treatment there was no significant difference in lifespan between the two groups. ^[5] That is, it has not been shown to extend lifespan in mammals; the worm finding cannot be transferred to humans.

The same study also looked at how humanin level changes with age across species. In rhesus monkeys, the blood level fell markedly between ages 19 and 25 but not between 25 and 35; in mice, it decreased about 40% in the first 18 months. In the naked mole-rat, a very long-lived rodent that shows few signs of aging, the level stayed constant for about 20 years. In cell lines carrying the mutation of the mitochondrial disease MELAS, the humanin level fell as the proportion of mutant mitochondria increased. ^[5] These observations suggest that humanin might be an indicator of mitochondrial health; but a low indicator does not mean that giving it externally would be beneficial.

A similar distinction is seen in the 2009 rat study: humanin’s effect on the liver occurred through the brain, disappeared when the signaling pathway in the hypothalamus was suppressed, and no direct effect was seen in isolated liver cells. ^[3] In the memory study in aged mice, the finding accompanying the improvement was not new nerve cell formation but a decrease in the number of activated immune cells in the brain (microglia). ^[4]

What is known about humanin in humans?

In humans, humanin has been studied only as a biomarker measured in blood or cerebrospinal fluid. These studies yield the result “humanin level is different in this condition”; they do not show that giving humanin corrects anything.

The findings in the table do not point in one direction. The authors of the 2020 study themselves state that studies of the relationship with humanin level in humans have not given clear results. ^[5] In the Swedish study, the resting level was seen to increase with age; this contradicts the generalization “humanin falls with age.” ^[6] The PCOS study from Türkiye, in turn, suggests that the low blood level does not stem from a decrease in muscle tissue. ^[7]

Where does the evidence come from?

A significant portion of humanin’s animal and human association data on aging and metabolism comes from the same research network. In the 2018 study, the senior author declares being a consultant and shareholder of a company developing mitochondrial peptide analogs, and the first author declares being a former consultant of this company; in the 2020 study, the senior author and one coauthor are consultants and shareholders of the same company. ^{[4] [5]} In the 2009 rat study, the authors declared no conflict of interest. ^[3]

Has humanin been tried in humans?

No. As of October 19, 2026, a “humanin” search on ClinicalTrials.gov gives seven records. In all of them, humanin is a marker measured in blood, muscle tissue, or at the gene-expression level in conditions such as acute kidney injury, heart surgery, PCOS, cerebral palsy, dialysis, or anesthesia; in no record is humanin or an analog given to participants as an intervention. ^[9] There is therefore no dose, efficacy, or safety information in humans.

Is it safe? The cancer concern

There are no human safety data. In animal data, however, there is a notable signal. In a 2020 study, the researchers observed that humanin was increased in triple-negative breast cancer biopsies compared with healthy breast tissue. In culture, adding humanin protected cancer cells against programmed cell death, while silencing humanin reduced cell viability and increased sensitivity to chemotherapy. Humanin given systemically to tumor-bearing mice accelerated tumor growth and the development of spontaneous lung metastasis and reduced the antitumor and antimetastatic effect of chemotherapy. The authors concluded that caution is needed when using externally given humanin to treat degenerative diseases. ^[8]

This is an animal finding and does not prove cancer risk in humans; but it points out that humanin’s “protecting the cell from death” effect might also protect cancer cells. Beyond this, the unknowns are these: time in the body in humans, immune response, and safety in pregnancy and long-term use. General injection-related risks are covered in a separate guide: Peptide side effects

FDA, WADA, and Türkiye: what is the legal status?

United States

In FDA’s May 14, 2026 nomination list for 503A (pharmacy compounding), humanin is in none of category 1 (under evaluation), category 2 (significant safety risk), or category 3; that is, it is not a bulk substance that has been taken under evaluation for compounding. ^[10] The legal and practical meaning of the “for research purposes” label is covered in a separate guide: What does research peptide mean?

Sport (WADA)

Humanin is not named in the WADA list valid from January 1, 2026; MOTS-c from the same family, by contrast, is named among AMPK activators in section S4.4.1. Section S0 of the list prohibits at all times, in and out of competition, any pharmacological substance not covered by later sections and not approved by any governmental health authority for human therapeutic use, for example drugs in preclinical development. ^[11] Published intervention data on humanin are at the preclinical level; the classification of a specific substance is within WADA’s authority.

Türkiye

The October 16, 2026 TİTCK Licensed Human Medicinal Products List contains no product with humanin as active ingredient. ^[12] Article 19 of Law No. 1262 punishes with imprisonment of one to five years those who manufacture unlicensed preparations and those who knowingly sell, offer for sale, or have them sold; the same penalty is provided for those who sell or advertise a product with the claim of diagnosing or treating diseases even if it is not a preparation. Importing unlicensed preparations for commercial purposes counts as smuggling. ^[13] Under Article 24 of Law No. 6197, medicines cannot be sold online or in any other electronic medium. ^[14]

The general legal framework for peptides: Are peptides legal?

Evidence table: claim, population, and limits

Limits of this guide

This page summarizes published cell, animal, and observational human studies on humanin and documents from official institutions. It gives no dose, cycle, preparation, administration technique, or product-sourcing information; procedures in animal studies cannot be transferred to humans. The one peptide that targets mitochondria and has a licensed indication is covered in a separate guide: SS-31 (Elamipretide)